Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Leukemia, Myeloid, Acute 124Multiple Myeloma 84Precursor Cell Lymphoblastic Leukemia-Lymphoma 76Lymphoma 73Lymphoma, Non-Hodgkin 66Leukemia 66Myelodysplastic Syndromes 56Hodgkin Disease 53Lymphoma, Large B-Cell, Diffuse 37Lymphoma, Mantle-Cell 33Breast Neoplasms 32Neuroblastoma 30Leukemia, Lymphocytic, Chronic, B-Cell 30Burkitt Lymphoma 30Lymphoma, Follicular 26Leukemia, Myelogenous, Chronic, BCR-ABL Positive 26Recurrence 24Sarcoma 18Neoplasms, Plasma Cell 18Hematologic Neoplasms 18Central Nervous System Neoplasms 18Lymphoma, B-Cell, Marginal Zone 17Leukemia, Biphenotypic, Acute 16Myeloproliferative Disorders 15Lymphoma, Large-Cell, Immunoblastic 15Congenital Abnormalities 15Brain Neoplasms 14Leukemia, Myelomonocytic, Chronic 13Anemia, Refractory, with Excess of Blasts 13Medulloblastoma 12

Interventions

Etoposide 3Carboplatin 3tremelimumab 1etoposide phosphate 1durvalumab 1Surgical Procedures, Operative 1Spinal Puncture 1Specimen Handling 1Radiotherapy, Intensity-Modulated 1Radiotherapy, Conformal 1Radiotherapy 1Photochemotherapy 1Paclitaxel 1Magnetic Resonance Spectroscopy 1Ifosfamide 1Granulocyte Colony-Stimulating Factor 1Drug Therapy 1Dihematoporphyrin Ether 1Cyclophosphamide 1Cisplatin 1Bleomycin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Germinoma × Granulocyte Colony-Stimulating Factor × Clear all
NCT02375204 2025-01-13

Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients with Relapsed or Refractory Germ Cell Tumors

Alliance for Clinical Trials in Oncology

Phase 3 Active not recruiting
420 enrolled

Nonseminomatous germ cell tumor, Choriocarcinoma, Neoplasms, Germ Cell and Embryonal, Teratoma, Germinoma, Seminoma, Endodermal Sinus Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡